Medicare Disease Management in Policy Context

Interim results of the Medicare health support demonstration projects suggest that commercial disease management (DM) is unable to deliver short term medical cost savings. This is not surprising given the current DM program focus on compliance with process measures that may only lead to cost savings in the long term.